Merck & Co. Remains 'Very Confident' In TIGIT

Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.

bull
Merck remains bullish about TIGIT prospects • Source: Shutterstock

Investors and stakeholders across the industry are keeping a close eye on a potential cancer drug target – TIGIT – that could be effective in combination with PD-1/L1 drugs. Several drug makers are investing in the class of drugs, which are in late-stage clinical testing, but the first Phase III data readout in the class of drugs from Roche Holding AG last year was disappointing, raising uncertainty about how other data readouts will play out.

Merck & Co., Inc. and Roche, two of the companies investing heavily in the area, both reported quarterly financial...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category